Study patients
cancer, adynamic bone disease
RHEUMATOID ARTHRITIS, CANCER, HYPERCALCEMIA
Forty-two primary kidney-only adult recipients, above 18 years of age, who received a kidney transplant from a living donor and had stable graft function, along with an eGFR of more than 30 ml/min per 1.73 m2 within two weeks of transplantation were enrolled in the study. Patients with a history of prior transplantation, immunosuppression, cancer, rheumatoid arthritis, hypo- or hypercalcemia, adynamic bone disease (PTH levels below 150ng/L), pregnancy, weight over 105 kg, previous parathyroidectomy, treatment with corticosteroids for more than three months before transplantation, treatment with calcitonin and bisphosphonates, and parathyroid level of more than 800 pg/ml were excluded.